Trial reportMolecular oncology2017
Cell-free DNA copy number variations in plasma from colorectal cancer patients.
Trial report in Molecular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03486431 (A Phase I Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy), which is not on this map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy (SABR) for Non-spine Bone & Lymph Node Oligometastates
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.International journal of molecular sciences · 2018Pooled it
- Cross-Cancer Detectability of ctDNA Biomarkers in Asian Populations: Implications for Pan-Cancer Detection.Cancer management and research · 2026Review
- From multi-omics to deep learning: advances in cfDNA-based liquid biopsy for multi-cancer screening.Biomarker research · 2025Review
- Understanding the cellular and molecular heterogeneity in colorectal cancer through the use of single-cell RNA sequencing.Translational oncology · 2025Article
- Stoichiometric constraints for detection of EV-borne biomarkers in blood.Journal of extracellular vesicles · 2025Review
- A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer.Oncology reviews · 2025Review
- Early Detection, Precision Treatment, Recurrence Monitoring: Liquid Biopsy Transforms Colorectal Cancer Therapy.Current cancer drug targets · 2025Review
- Diagnosis of colorectal cancer based on folate receptor-positive circulating tumor cell analysis: a retrospective cohort study.International journal of clinical oncology · 2024Article
- The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples.Frontiers in cell and developmental biology · 2024Review
- Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.Frontiers in molecular biosciences · 2024Review
- Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies.International journal of molecular sciences · 2023Review
- Review
- Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer.Exploration of targeted anti-tumor therapy · 2023Review
- Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors.Biomedicines · 2022Review
- Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer.International journal of molecular sciences · 2022Article
- Properties and Application of Cell-Free DNA as a Clinical Biomarker.International journal of molecular sciences · 2021Review
- Cell-free DNA in the surveillance of heart transplant rejection.Indian journal of thoracic and cardiovascular surgery · 2021Review
- Development of MR-based preoperative nomograms predicting DNA copy number subtype in lower grade gliomas with prognostic implication.European radiology · 2021Article
- An Improved Detection of Circulating Tumor DNA in Extracellular Vesicles-Depleted Plasma.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To evaluate the clinical utility of cell-free DNA (cfDNA), we performed whole-genome sequencing to systematically examine plasma cfDNA copy number variations (CNVs) in a cohort of patients with colorectal cancer (CRC, n = 80), polyps (n = 20), and healthy controls (n = 35). We initially compared cfDNA yield in 20 paired serum-plasma samples and observed significantly higher cfDNA concentration in serum (median = 81.20 ng, range 7.18-500 ng·mL
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.